Amendment to Current Report (Form 8-K/A)

For immediate release

October 29, 2025

AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

•Worldwide revenue of $134.3 million - an increase of 15.8% year over year (15.1% constant currency)

•Net loss of $0.3 million - an improvement of $7.6 million year over year

•Adjusted EBITDA of $17.8 million - an increase of $9.9 million year over year

•Generated $30.1 million of cash in the third quarter and $25.1 million year to date

MASON, Ohio, October 29, 2025 - AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2025 financial results.

"Our third quarter results demonstrate strong execution and patient focus across the business. We are seeing continued positive traction with our most recent product launches, including our AtriClip platform and cryoSPHERE devices, coupled with durable momentum from expanding adoption of our EnCompass clamp," said Michael Carrel, President and Chief Executive Officer at AtriCure. "As we invest in product innovation and clinical science to build catalysts for the future, we are determined to drive exceptional financial performance, underscored by continued growth and increasing profitability."

Third Quarter 2025 Financial Results

Revenue for the third quarter 2025 was $134.3 million, an increase of 15.8% over third quarter 2024 revenue (15.1% on a constant currency basis), reflecting continued adoption of our products and therapies by physicians globally. U.S. revenue was $109.3 million, an increase of $13.9 million or 14.5%, compared to the third quarter 2024. U.S. revenue growth was driven by sales across key product lines, highlighted by the AtriClip® FLEX·Mini™ device for appendage management, the EnCompass® clamp for open ablation and the cryoSPHERE MAX™ probe for post-operative pain management. International revenue increased $4.5 million or 22.0% (17.9% on a constant currency basis) to $25.0 million, with broad growth across franchises and geographic regions.

Gross profit for the third quarter 2025 was $101.3 million compared to $86.8 million for the third quarter 2024. Gross margin was 75.5% for the third quarter 2025, an increase of 59 basis points from the third quarter 2024, reflecting favorable product mix. Income from operations for the third quarter 2025 was $0.2 million, compared to a loss from operations of $7.4 million for the third quarter 2024. Basic and diluted net loss per share was $0.01 for the third quarter 2025, compared to $0.17 for the third quarter 2024.

Adjusted EBITDA for the third quarter 2025 was $17.8 million, an increase of $9.9 million from the third quarter of 2024. Adjusted loss per share for the third quarter 2025 was $0.01, compared to $0.17 for the third quarter 2024.

Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP financial measures. We discuss these non-GAAP financial measures and provide reconciliations to GAAP measures later in this release.

2025 Financial Guidance

Full year 2025 revenue is now projected to be approximately $532 million to $534 million, and management now expects full year 2025 Adjusted EBITDA of approximately $55 million to $57 million. Full year 2025 adjusted loss per share is expected to be in the range of $0.23 to $0.26. Additionally, management continues to expect cash flow generation for the full year 2025.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, October 29, 2025 to discuss third quarter 2025 financial results. To access the webcast, please visit the Investors page of AtriCure's corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.